UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

PCN8 Axitinib (AXI) and Best Supportive Care (BSC) in the Treatment of Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma (mRCC): Results of a Simulated Treatment Comparison (STC) Analyses

Value in health, 2012-11, Vol.15 (7), p.A410-A410

2012

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review

Clinical oncology (Royal College of Radiologists (Great Britain)), 2012-08, Vol.24 (6), p.410-412

2012

Link zum Volltext

Verfügbarkeit prüfen

Primary Excision Margins and Sentinel Lymph Node Biopsy in Clinically Node-negative Melanoma of the Trunk or Extremities

Clinical oncology (Royal College of Radiologists (Great Britain)), 2011-11, Vol.23 (9), p.569-571

2011

Link zum Volltext

Verfügbarkeit prüfen

Pharmacist and nurse led melanoma immunotherapy clinic

Annals of oncology, 2019-10, Vol.30, p.v832

2019

Link zum Volltext

Verfügbarkeit prüfen

CN70 - Pharmacist and Nurse (PN) led melanoma immunotherapy clinic: Patient experience survey

Annals of oncology, 2019-10, Vol.30, p.v836-v836

2019

Link zum Volltext

Verfügbarkeit prüfen

Pharmacist and Nurse (PN) led melanoma immunotherapy clinic: Patient experience survey

Annals of oncology, 2019-10, Vol.30, p.v836

2019

Link zum Volltext

Verfügbarkeit prüfen

CN58 - Pharmacist and nurse led melanoma immunotherapy clinic

Annals of oncology, 2019-10, Vol.30, p.v832-v832

2019

Link zum Volltext

Verfügbarkeit prüfen

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy

Annals of oncology, 2020-08, Vol.31 (8), p.1075-1082

2020

Link zum Volltext

Verfügbarkeit prüfen

915PD - Diagnosis, management, and burden of renal cell carcinomas: Results from a global patient survey in 43 countries

Annals of oncology, 2019-10, Vol.30, p.v364-v364

2019

Link zum Volltext

Verfügbarkeit prüfen

Diagnosis, management, and burden of renal cell carcinomas: Results from a global patient survey in 43 countries

Annals of oncology, 2019-10, Vol.30, p.v364

2019

Link zum Volltext

Verfügbarkeit prüfen

910PD - Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S)

Annals of oncology, 2019-10, Vol.30, p.v361-v361

2019

Link zum Volltext

Verfügbarkeit prüfen

Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL

Annals of oncology, 2019-10, Vol.30, p.v891-v892

2019

Link zum Volltext

Verfügbarkeit prüfen

LBA73 - SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)

Annals of oncology, 2019-10, Vol.30, p.v908-v910

2019

Link zum Volltext

Verfügbarkeit prüfen

Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial

Annals of oncology, 2019-10, Vol.30, p.v906

2019

Link zum Volltext

Verfügbarkeit prüfen

Homogenisation of leftover surgical tissue across multiple cancer types: A feasibility study (HoLST-F)

Annals of oncology, 2019-10, Vol.30, p.v796

2019

Link zum Volltext

Verfügbarkeit prüfen

ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma

Annals of oncology, 2019-10, Vol.30, p.v359

2019

Link zum Volltext

Verfügbarkeit prüfen

1980TiP - Homogenisation of leftover surgical tissue across multiple cancer types: A feasibility study (HoLST-F)

Annals of oncology, 2019-10, Vol.30, p.v796-v796

2019

Link zum Volltext

Verfügbarkeit prüfen

LBA56 - Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL

Annals of oncology, 2019-10, Vol.30, p.v891-v892

2019

Link zum Volltext

Verfügbarkeit prüfen

SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)

Annals of oncology, 2019-10, Vol.30, p.v908-v910

2019

Link zum Volltext

Verfügbarkeit prüfen

LBA69 - Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial

Annals of oncology, 2019-10, Vol.30, p.v906-v906

2019

Link zum Volltext

Verfügbarkeit prüfen

907PD - ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma

Annals of oncology, 2019-10, Vol.30, p.v359-v359

2019

Link zum Volltext

Verfügbarkeit prüfen

5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma

Annals of oncology, 2019-10, Vol.30, p.v904-v905

2019

Link zum Volltext

Verfügbarkeit prüfen

EULAR recommendations for the diagnosis and the management of rheumatic immune-related adverse events due to cancer immunotherapy

Annals of oncology, 2019-10, Vol.30, p.v528

2019

Link zum Volltext

Verfügbarkeit prüfen

First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A

Annals of oncology, 2019-10, Vol.30, p.v381-v382

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(34)
Tagungsberichte
(2)

Sprache

Englisch
(36)

Erscheinungsjahr

n.n

Thema

Science & Technology
(8)
Humans
(6)
Life Sciences & Biomedicine
(6)
Oncology
(5)
Engineering
(2)
Engineering, Electrical & Electronic
(2)
Female
(2)
Hematology, Oncology And Palliative Medicine
(2)
Kidney Neoplasms - Drug Therapy
(2)
Laser Modes
(2)
Male
(2)
Melanoma - Drug Therapy
(2)
Melanoma - Pathology
(2)
Optics
(2)
Physical Sciences
(2)
Radiology
(2)
Skin Neoplasms - Drug Therapy
(2)
Skin Neoplasms - Pathology
(2)
Technology
(2)
Adjuvant Therapy
(1)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

PCN8 Axitinib (AXI) and Best Supportive Care (BSC) in the Treatment of Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma (mRCC): Results of a Simulated Treatment Comparison (STC) Analyses

Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review

Primary Excision Margins and Sentinel Lymph Node Biopsy in Clinically Node-negative Melanoma of the Trunk or Extremities

Pharmacist and nurse led melanoma immunotherapy clinic

CN70 - Pharmacist and Nurse (PN) led melanoma immunotherapy clinic: Patient experience survey

Pharmacist and Nurse (PN) led melanoma immunotherapy clinic: Patient experience survey

CN58 - Pharmacist and nurse led melanoma immunotherapy clinic

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy

915PD - Diagnosis, management, and burden of renal cell carcinomas: Results from a global patient survey in 43 countries

Diagnosis, management, and burden of renal cell carcinomas: Results from a global patient survey in 43 countries

910PD - Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S)

Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL

Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S)

LBA73 - SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)

Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial

Homogenisation of leftover surgical tissue across multiple cancer types: A feasibility study (HoLST-F)

ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma

1980TiP - Homogenisation of leftover surgical tissue across multiple cancer types: A feasibility study (HoLST-F)

LBA56 - Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL

SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)

LBA69 - Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial

907PD - ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma

5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma

EULAR recommendations for the diagnosis and the management of rheumatic immune-related adverse events due to cancer immunotherapy

First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A

Suchergebnisse filtern